Cognitive function and depression in symptom resolution in schizophrenia patients treated with an atypical antipsychotic

Brain and Cognition
E Stip, Adham Mancini-Marïe

Abstract

To investigate which cognitive and affective features contribute most to responder/non-responder group separation during a switching trial with atypical antipsychotic. A prospective open trial with an atypical antipsychotic (olanzapine). One hundred and thirty-four patients meeting diagnostic criteria for schizophrenia, schizophreniform or schizoaffective disorder began an 8-week open-label olanzapine treatment at a dose of 5 mg/day which was increased to 10 mg/day after one week. Olanzapine during 8 weeks. Patients were considered as responders if their BPRS score decreased of at least 20% (n = 96) and non-responders if it did not (n = 38). Neuropsychological assessments were carried out at baseline, at four and at eight weeks. Neurocognitive measures were analyzed for discriminate factors between responder and non-responder groups. A regression analysis was applied to explain the effects of depression on each cognitive variable. Depression was found to be a weak discriminant factor, however this finding could not firmly establish that depression is a potential factor in explaining deficits and improvements in cognition.

References

Feb 1, 1994·Schizophrenia Research·D AddingtonE Maticka-Tyndale
Feb 23, 2000·European Psychiatry : the Journal of the Association of European Psychiatrists·E StipP Liddle
Aug 16, 2003·Journal of Clinical Psychopharmacology·Emmanuel StipUNKNOWN Canadian Switch Study Group

❮ Previous
Next ❯

Citations

Jul 16, 2008·Cognitive Neuropsychiatry·Stéphane PotvinEmmanuel Stip
Jan 1, 2006·International Journal of Psychiatry in Clinical Practice·Young-Hoon KoSeung-Hyun Kim

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here